Long QT syndrome 2 (LQTS2) caused by missense mutations in hERG channel is clinically associated with abnormally prolonged ventricular repolarization and sudden cardiac deaths. Modelling monogenic arrhythmogenic diseases using human-induced pluripotent stem cells (hiPSCs) offers unprecedented mechanistic insights into disease pathogenesis. We utilized LQTS2-hiPSC-derived cardiomyocytes (CMs) to elucidate pathological changes and to demonstrate reversal of LQTS2 phenotype in a therapeutic intervention using a pharmacological agent,
Introduction
Hereditary long QT syndrome (LQTS) is a genetic disorder caused by mutations in one or more ion channel subunits expressed in the heart. 1,2 LQTS is characterized by delayed or prolonged cardiac repolarization in the electrocardiogram with increased risks of developing polymorphic ventricular tachycardia (torsade de pointes), syncope, and sudden cardiac death. 2, 3 To date, LQTS has been associated with over 500 different mutations in at least 13 genes encoding cardiac ion channel proteins. 4 Genotype-to-phenotype penetrance is estimated to be 60-70% depending on location of the mutation, with more severe phenotypes arising from mutations around the pore-forming regions. 4 LQTS2 implicates hERG (encoded by KCNH2 gene), which constitutes pore-forming a subunit of the rapidly activating delayed rectifier potassium current (I Kr ). 5 Heterozygote KCNH2 mutations exert a dominant-negative effect on wild-type hERG channel-associated I Kr currents 5, 6 by impaired trafficking pathways or altered channel kinetics of the resulting co-assembled hERG heterotetramers. 6, 7 Current noncardiac heterologous expression systems in HEK 293 or CHO cells 8, 9 have implicated endoplasmic reticulum (ER) sequestering of hERG 6, 8 as a probable cause of LQTS2 manifestation. 6 However, inability to accurately model the disease in heterologous systems 10 and the lack of in vitro humanized diseased cardiomyocytes (CMs) have significantly hindered a true mechanistic understanding of this disease. Disease-specific-induced pluripotent stem cells offer unique opportunity for disease modelling. 10, 11 Such models yield previously unavailable insights into the molecular basis of disease manifestations that could serve as an invaluable platform for risk stratification and drug discovery. In this study, we show that CMs derived from LQTS2 patientspecific (A561V mutant) human-induced pluripotent stem cells (hiPSCs) recapitulate the disease phenotype with defective trafficking of hERG channel in vitro and demonstrate phenotypic reversal through pharmacological intervention of ER-Golgi export machinery.
Methods
Reprogramming of patient-derived skin fibroblasts was performed with episomal plasmids as reported previously. 12, 13 For details of culture, cardiac differentiation, and characterization, please refer to Supplementary material online, Method section. All human studies were performed conform to the declaration of Helsinki, and all experimental protocols and studies were approved by the Institutional Review Board (IRB) of the host institute.
Teratoma formation
Animal experiments were conducted following experimental protocols approved by the Institutional Ethics Committee on Experimental Animals, in full compliance with Singapore laws and regulations and followed the guidelines by the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. SCID mice, 6-week old, weighing 20 -23 g, were obtained from SingHealth Experimental Medicine Centre and were anaesthetized with 2% isofluorane initially followed by 1% isofluorane during surgery. Approximately 1 × 10 6 hiPS cells were injected into the kidney capsule as previously described. 13, 14 Mice were euthanized with carbon dioxide asphyxiation at 8 weeks after injections and tumours collected, fixed, and processed for standard H&E staining.
Microelectrode array recordings
To characterize the electrophysiological properties of the hiPS-CMs, a microelectrode array (MEA) recording system (Multichannel Systems, Reutlingen, Germany) was used as described previously. 13, 15 Briefly, contracting areas were micro-dissected and plated on MEA plates, allowed to adjust for 72 h before recording. All stock drugs were diluted in medium (2 mL) to assess the effects on the electrophysiological properties. All extracellular recordings were performed for 180 s at baseline and at 5 min after drug application at 378C. Data were recorded using the MC Rack software (Multichannel System), and the recordings were used to determine the local field potential duration (FPD). FPD measurements were normalized (corrected FPD, cFPD) to the beating rate of the contracting areas with the Bazzet correction formula: cFPD ¼ FPD/ p (RR interval). 16 
Whole-cell patch-clamp recordings
Spontaneously contracting embryoid bodies were enzymatically dissociated into single cells with 1 mg/mL of collagenase IV and attached on glass bottom dishes. Action potentials were recorded in the current-clamp mode and triggered with just-threshold 4 ms current steps at a stimulation rate of 1 Hz until a steady state was reached with external buffer at 378C. Whole patch-clamp recording was performed with an Axopatch 700B amplifier (Axon Instrument, Foster City, CA, USA). The pClamp software (Version 10.0; Axon Instrument) was used to acquire and analyse data. For voltageclamp studies of I Kr , nimodipine (1 mM) was added to the external solution to block the L-type Ca 2+ current. Na + and T-type Ca 2+ currents were inactivated by holding potential of 240 mV. I Kr was defined as the E-4031-sensitive (1 mM) current. The holding potential was at -40 to +50 mV in 10 mV increments, lasting 5 s. Tail current was recorded after the test potential was backed to -40 mV.
Statistical analysis
Results were reported as mean + standard error of mean (SEM). Comparison between LQTS2-hiPSC-CMs and healthy control-hiPSC-CMs groups was performed using the Student's t-test. One-way analysis of variance (ANOVA) followed by Tukey's post hoc tests was used when comparing multiple groups. A P-value ,0.05 was considered statistically significant.
Results

Generation and characterization of LQTS2-hiPSC
Dermal fibroblasts were collected from a 13-year-old male (only child of the family), who presented clinical episode of polymorphic ventricular tachycardia ( Figure 1A ) with a heart rate-corrected (QTc) of 584 ms ( Figure 1B ). The patient is currently managed with a beta-blocker (atenolol) and an implantable defibrillator. Genetic screening showed that patient fibroblast exhibited a C1682T heterozygous missense mutation in KCNH2 resulting in an A561V substitution in the S5 transmembrane domain ( Figure 1C ). We generated two viral-free LQTS2-hiPSC lines that showed visual morphologies similar to hESC colonies (compact colonies, high nucleus-to-cytoplasm ratios, and prominent nucleoli). Fibroblasts from healthy individual were used to generate normal control iPSC lines. 13 Immunostaining and flow cytometric analysis for controland LQTS2-hiPSCs showed expression of hallmark pluripotency markers, OCT4, SSEA4, TRA-1-60, and TRA-1-81 ( Figure 2A ) in over 95% of the cells with the normal karyotype ( Figure 2B ; Supplementary material online, Figure S1 -2). Genetic screening of the generated LQTS2-hiPSC also exhibited a C1682T heterozygous missense mutation, which was absent in control hiPSC lines ( Figure 2C and Supplementary material online, Figure S3 ). These hiPSCs also demonstrated high levels of pluripotency transcripts, showed no genetic integration of episomal vectors (Supplementary material online, Figure S4 ), were able to form teratomas with cell derivatives of three germ layers following injection in SCID mice ( Figure 2D ) and expressed characteristic ecto-/meso-/ endodermal genes via spontaneously differentiated embryoid body (EB) in vitro (Supplementary material online, Figure S5 ).
Cardiac characterization and electrophysiology of LQTS2
Spontaneously contracting areas were visible 12-14 days postdifferentiation via an EB-based protocol (Supplementary material online, Movies S1 and S2) in control-and LQTS2-hiPSCs with similar efficiencies. Positive staining of dissociated contracting clusters with sarcomeric a-actinin, myosin light chain-2, titin, and SERCA2a confirmed cardiac morphology ( Figure 2E and Supplementary material online, Figures S6 and S7) . Furthermore, quantitative gene expression of cardiacspecific transcriptional, structural, and functional markers confirmed normal cardiac ontogeny of both our control-and LQTS2-hiPSC lines (Supplementary material online, Figure S8 ). We then performed cardiac electrophysiology in control-and LQTS2-CMs at single-cell level using the patch-clamp technique and evaluating functional syncytium at multicellular levels by MEA. MLC2v-specific Smartflare TM RNA detection probes were utilized to identify ventricular myocytes (Supplementary material online, Figure S9 ) and consistent with LQTS electrophysiology, 10,17 current-clamp recording of LQTS2 ventricular and atrial myocytes showed prolonged action potential duration (APD) with APD 70/90 lengthening 1.9-folds more than those in control myocytes with 1 Hz pacing ( Figure 3A and B, and Supplementary material online, Table S2 ).
Consistent with single-cell patch-clamp studies, extracellular field potential recordings of the LQTS2-EBs ( Figure 3C ) demonstrated significant prolongation in beating rate-cFPD when compared with control-EBs (Control-EBs vs. LQTS2-EBs: 0.368 + 0.02 vs. 0.579 + 0.02 s, n ¼ 20, P , 0.001). Furthermore, in single-cell voltage-clamp studies, LQTS2 ventricular myocytes (detected using MLC2v Smartflare TM RNA detection probes, n ¼ 9) showed a substantially reduced E-4031 (a specific I Kr blocker)-sensitive currents ( Figure 3D ). At +40 mV, peak and tail I Kr currents depressed by 80 and 90%, respectively, than in control cells ( Figure 3E ). Interestingly, LQTS2-EBs (n ¼ 75/100 EBs screened) demonstrated spontaneous arrhythmogenic events (75%; Figure 3F ) that were not observed in control-EBs (n ¼ 50). Similarly, some arrhythmogenic events were also recorded at single-cell levels during spontaneous contraction ( Figure 3F ).
Contracting EBs from control and LQTS2 were also evaluated with drugs that may ameliorate or aggravate the disease phenotype. 18 About 100 nM E-4031 increased cFPDs significantly in both cell types, but LQTS2-contracting EBs demonstrated pronounced occurrence of early after depolarizations (EADs; n ¼ 14/15; Supplementary material online, Figure S10 ) when compared with the controls (n ¼ 2/15). Furthermore, addition of isoproterenol to LQTS2-EBs increased beating frequencies and reduced cFPDs, with aggravating arrhythmogenic episodes. Subsequent treatment with b-adrenoreceptor antagonist, atenolol reduced the beating frequencies and restored cFPDs (Supplementary material online, Figure S10 ). These results collectively confirmed that our LQTS2-CMs manifested hERG dysfunction that is of value for disease modelling. 
LQTS2 myocytes express more mutant allele and non-glycosylated hERG
In order to correlate electrophysiological changes in LQTS2-CMs with dysfunctional hERG, we performed PCR and observed that the mutant KCNH2 allele was significantly overexpressed in comparison with wildtype allele in LQTS2-CMs ( Figure 4A) . Furthermore, allele-specific pyrosequencing confirmed that, in LQTS2-CMs, 67% of the KCNH2 transcripts were dominated by the mutant allele ( Figure 4B ), whereas both alleles showed equal dominance in undifferentiated LQTS2-iPSC (Supplementary material online, Figure S11 ).
This allelic dominance was consistent with LQTS2-CM hERG western blots that showed more non-glycosylated (immature) hERG when compared with controls ( Figure 4C) . Immunostaining of hERG in LQTS2-CMs further confirmed a significant reduction (three-fold) in sarcolemmal localization densities (Figure 4Dvi and E-F) compared with control-CMs (Figure 4Diii , E, and F, and Supplementary material online, Figure S12 ). Furthermore, LQTS2-CMs showed a significant sequestering of hERG (four-fold; Figure 4Dv and F ) in the perinuclear area (ER; Supplementary material online, Figure S13 ) when compared with control-CMs (Figure 4Dii and F ) . These results taken together suggest that mutant allele caused sequestration of hERG channel in the ER, indicative of a trafficking defect of hERG in our LQTS2-CMs.
Chaperone and trafficking defects in LQTS2-CMs
To confirm hERG trafficking dysfunction, we investigated key players in calpain and proteosomal systems that are integral in protein trafficking. Quantitative gene expression analysis of LQTS2-CMs showed a significant up-regulation of Ca 2+ -activated cysteine protease family (calpain) members, CAPN1 (2.5-folds), CAPN2 (two-folds), and CAPN3 19 (1.5-folds), compared with controls ( Figure 5A ). Expression of CAST (calpastatin) 20 also showed a two-fold increase in LQTS2-CMs ( Figure 5A ), but was substantially accumulated in the perinuclear area ( Figure 5Biv ) when compared with control-CMs (Figure 5Bi) . We also observed significantly increased gene expression of HSP90 (five-fold), HSP70 (2.5-fold), UBB (ubiquitin; three-fold), and CAV3 (caveolin 3; 21 50-fold; Figure 5A ). However, unlike LQTS2-CMs, such changes were not observed in undifferentiated LQTS2-hiPSCs or patient fibroblasts ( Figure 5C ). Immunostaining of hERG and hsp70 in LQTS2-CMs showed that they co-localized in the ER (Supplementary material online, Figure S13 ), while immunoprecipitation studies confirmed interactions between hERG and hsp70 (Supplementary material online, Figure S13 ).
Re-trafficking of hERG by ALLN
As trafficking was implicated in our results, we treated the LQTS2-CMs with 10 mM
, a known calpain 1/2 and proteasome inhibitor, which had previously shown to rescue overexpressed mutated hERG in HEK heterologous systems. 9 Post-ALLN treatment (42 h), western blots showed a significant increase in glycosylated (mature) hERG in LQTS2-CMs when compared with untreated LQTS2-CMs ( Figure 4C ).
In comparison with untreated LQTS2-CMs, membrane density plot of hERG immunostaining demonstrated increased peak numbers ( Figure 4E ) and enhanced sarcolemmal localization (two-fold) with corresponding reduction (66%) in perinuclear hERG retention following ALLN treatment (Figure 4Dvi and F ) . These results suggested that blocking the proteasomal pathway with ALLN could re-traffick sequestered LQTS2 and trafficking hERG towards sarcolemma of LQTS2-CMs. ALLN-treated LQTS2-CMs also showed down-regulated expression of CAPN1 (50%), CAPN2 (25%), and CAPN3 (80%) with corresponding reduction in CAST (40%), UBB (25%), HSP70 (50%), and CAV3 (60%) gene expression levels with the exception of HSP90 (four-fold increase) ( Figure 5A ). These changes were corroborated by the western blot of calpain 3, calpastatin, Hsp90, and Hsp70 proteins that confirmed trafficking pathway modulation by ALLN ( Figure 5D ). Furthermore, reduced calpastatin production was reflected by subdued perinuclear staining in the ALLN-treated LQTS2-CMs (Figure 5Bvi ).
ALLN rescued LQTS2-CM show phenotypic correction of repolarization
Next, we evaluated if hERG re-trafficking induced by ALLN could reduce prolonged repolarization of LQTS2-CMs. MEA recordings of ALLNtreated LQTS2-EBs clearly demonstrated a time-dependent reduction in cFPDs when compared with untreated LQTS2-EBs ( Figure 6A and B) . ALLN reduced spontaneous arrhythmogenic episodes in the contracting EBs ( Figure 6A and Supplementary material online, Movie S3) and increased beating frequencies at 42 h exposure ( Figure 6C ) with more rhythmic contractions (Supplementary material online, Movie S3). In contrast, neither significant change in cFPDs nor waveform changes were observed in control-CMs treated with ALLN (Supplementary material online, Figure S14 ). Single-cell current-clamp recordings showed a marked reduction (1.5-fold) in APD 70/90 in both ventricular and atrial myocytes ( Figure 6D ALLN-treated LQTS2-CMs (213.8 + 3.9 mV; n ¼ 6) ( Figure 6H ), a significant restoration of slope factor post-ALLN treatment was observed ( Figure 6I ). These studies demonstrate that re-trafficking strategies could potentially rescue LQTS2 phenotype in hiPSC-derived CMs.
Discussion
In this study, we isolated skin fibroblasts from a patient carrying an autosomal-dominant missense KCNH2 mutation with C1682T (A561V) substitution in the S5 transmembrane domain 8 that is implicated in trafficking defective LQTS2. Similar to other KCNH2 mutations, A561V has been associated with variable clinical penetrance ranging from 25 to 90%. 22 -24 More interestingly, contrary to other known KCNH2 mutations, 25 A561V mutant has been reported to be not responsive to pharmacological rescue 8, 26 and insensitive to temperature-mediated functional recovery. 25 Amino acid at position 561 is a hot spot for LQTS2 mutations, 27, 28 where two other known mutations at A561P and A561T were similarly reported to lead to drastic reduction in I Kr currents. 8 Previous studies 4, 10 have demonstrated that KCNH2 mutants hiPSC-CMs treated with channel modulators could shorten APDs. Alternative approaches that target mutants with defective channel assembly that are insensitive to known pharmacological rescue, 8 such as A561V mutant in this study, would help to better understand diversity of LQTS2 manifestations. Reduced amplitude of I Kr currents in LQTS2-CMs shown previously 10,29 may be due to impaired channel conductance and decreased presence of sarcolemmal hERG channels. Our reduced membrane hERG by immunostaining and western blots corroborate well with these drastically reduced I Kr currents (80 -90%). Such reduction of functional hERG would translate to prolonged APD/cFPD and arrhythmogenesis (75% To reverse the trafficking-induced defects, LQTS2-CMs treated with ALLN blocked calpain and proteosomal complex, reducing HSP70 and CAV3 expression levels, indicative of attenuated hERG tagging 6, 26 and reduced turnover, 21 respectively. This resulted in misfolded hERG to escape HSP70/90 checkpoints and is re-trafficked to the membrane. Indeed, changes in HSP70/90 relationship and associated ubiquitination in channel maturation of hERG mutants have been previously demonstrated. 35 This together with decreased CAV3-mediated hERG turnover resulted in an increased sarcolemmal hERG and may result in an increased retention of glycosylated hERG as shown by our western blots. While this paper was under revision, Bellin et al. 34 demonstrated that proteosomal inhibitor lactacystin augmented the level of mature hERG in NKx2.5 eGFP/w hESC-derived CMs harbouring a N996I-induced LQTS2 mutation, though no confirmation of recovery of I Kr currents was performed following treatment. In this study, we, for the first time, demonstrate that functionality of the re-trafficked hERG channels by ALLN was able to increase I Kr currents and reduce cFPD in the LQTS2-CMs with alleviated spontaneous arrythymogenic episodes by voltage clamp and MEA studies. While V 1/2 activation did not change significantly, the slope factor of activation was significantly modified, demonstrating alterations of the hERG channel gating kinetics by A561V mutation and its reversal by ALLN treatment. Such effect of A561V hERG mutation on channel kinetics was similarly observed in the noncardiac heterologous system performed under temperature controlled settings 7 similar to ours, though differed from those recorded at room temperature. 9 Mechanism of differential KCNH2 allelic dominance observed in this study remains unclear. Selective expression of mutant allele in hiPSCCMs, but not undifferentiated hiPSC, would likely accentuate the dominant-negative effect of this A561V mutant. It is uncertain if our observation of such cell type-specific activation pattern of allelic gene expression has a role in phenotypic heterogeneity of LQTS2. Nevertheless, previous studies had indicated that gene dosage as one of the important determinants of LQTS2 phenotype, 24 which along with other unidentified modifiers, may contribute to differential clinical penetrance of the disease 24 that warrants specific attention in future studies. )
. Our results on re-trafficking of hERG demonstrate an alternative strategy that intervenes prolonged repolarization durations and suppresses arrhythmogenesis in LQTS2-CMs. ALLN as a broad-spectrum inhibitor of ubiquitin-proteasome pathway may open a platform for developing specific cellular targets, such as HSP70, 36 along the trafficking pathway of hERG. This strategy may have an advantage in targeting re-trafficable KCNH2 missense mutations in non-pore-forming regions of hERG channel that represent the majority of LQTS2 mutations, 6 as well as other channelopathies that are attributable to similar trafficking defects.
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